{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:27:26Z","timestamp":1790630846146,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329\u2009days. Patients also had detectable SARS-CoV-2-specific T cells and CD4\n                    <jats:sup>+<\/jats:sup>\n                    responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.\n                  <\/jats:p>","DOI":"10.1038\/s43018-021-00275-9","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T12:03:25Z","timestamp":1635336205000},"page":"1321-1337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-0981","authenticated-orcid":false,"given":"Annika","family":"Fendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8657","authenticated-orcid":false,"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-173X","authenticated-orcid":false,"given":"Scott T. C.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-6086","authenticated-orcid":false,"given":"Maddalena","family":"Cerrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Amanda","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Rzeniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-2641","authenticated-orcid":false,"given":"William","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille L.","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalinie","family":"Joharatnam-Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-6677","authenticated-orcid":false,"given":"Georgina H.","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-9867","authenticated-orcid":false,"given":"Martin","family":"Pule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-840X","authenticated-orcid":false,"given":"Leila","family":"Mekkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Carlyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyra Del","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Lingard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mangwende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ahmod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-8141","authenticated-orcid":false,"given":"Camila","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-9130","authenticated-orcid":false,"given":"Helen R.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Agua-Doce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Caidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-0079","authenticated-orcid":false,"given":"Michael","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-6171","authenticated-orcid":false,"given":"Mary","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cubitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-7940","authenticated-orcid":false,"given":"Harshil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Gavrielides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-8592","authenticated-orcid":false,"given":"Ambrosius P.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1464-8583","authenticated-orcid":false,"given":"James I.","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2459-3480","authenticated-orcid":false,"given":"Jerome","family":"Nicod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firza","family":"Gronthoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-4555","authenticated-orcid":false,"given":"Robyn L.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"van As","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Droney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-8011","authenticated-orcid":false,"given":"Kate C.","family":"Tatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-628X","authenticated-orcid":false,"given":"Shaman","family":"Jhanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-7023","authenticated-orcid":false,"given":"Olivia","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreerang","family":"Bhide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemency","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Slattery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Tippu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-7696","authenticated-orcid":false,"given":"Spyridon","family":"Gennatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Okines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. S.","family":"Furness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-340X","authenticated-orcid":false,"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-639X","authenticated-orcid":false,"given":"Steve","family":"Gamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Crick COVID-19 Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-4554","authenticated-orcid":false,"given":"Sacheen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-0025","authenticated-orcid":false,"given":"Nadia","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-2040","authenticated-orcid":false,"given":"Katalin A.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Swerdlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-2633","authenticated-orcid":false,"given":"George","family":"Kassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-136X","authenticated-orcid":false,"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The CAPTURE consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"275_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","volume":"139","author":"KS Saini","year":"2020","unstructured":"Saini, K. S. et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur. J. Cancer 139, 43\u201350 (2020).","journal-title":"Eur. J. Cancer"},{"key":"275_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436 (2020).","journal-title":"Nature"},{"key":"275_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garcia-Suarez","year":"2020","unstructured":"Garcia-Suarez, J. et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J. Hematol. Oncol. 13, 133 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"275_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino, M. C. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 21, 914\u2013922 (2020).","journal-title":"Lancet Oncol."},{"key":"275_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","volume":"395","author":"LY Lee","year":"2020","unstructured":"Lee, L. Y. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395, 1919\u20131926 (2020).","journal-title":"Lancet"},{"key":"275_CR6","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907\u20131918 (2020).","journal-title":"Lancet"},{"key":"275_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","volume":"32","author":"P Grivas","year":"2021","unstructured":"Grivas, P. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann. Oncol. 32, 787\u2013800 (2021).","journal-title":"Ann. Oncol."},{"key":"275_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW Lee","year":"2020","unstructured":"Lee, L. Y. W. et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 21, 1309\u20131316 (2020).","journal-title":"Lancet Oncol."},{"key":"275_CR9","doi-asserted-by":"publisher","first-page":"175883592097114","DOI":"10.1177\/1758835920971147","volume":"12","author":"VE Crolley","year":"2020","unstructured":"Crolley, V. E. et al. COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study. Ther. Adv. Med. Oncol. 12, 1758835920971147 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"275_CR10","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","volume":"26","author":"EV Robilotti","year":"2020","unstructured":"Robilotti, E. V. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 26, 1218\u20131223 (2020).","journal-title":"Nat. Med."},{"key":"275_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange, E. M. et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 27, 1280\u20131289 (2021).","journal-title":"Nat. Med."},{"key":"275_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","volume":"39","author":"S Abdul-Jawad","year":"2021","unstructured":"Abdul-Jawad, S. et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell 39, 257\u2013275.e256 (2021).","journal-title":"Cancer Cell"},{"key":"275_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","volume":"39","author":"A Thakkar","year":"2021","unstructured":"Thakkar, A. et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 39, 1081\u20131090.e2 (2021).","journal-title":"Cancer Cell"},{"key":"275_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cell.2020.09.005","volume":"183","author":"L Au","year":"2020","unstructured":"Au, L. et al. Cancer, COVID-19, and antiviral immunity: the CAPTURE study. Cell 183, 4\u201310 (2020).","journal-title":"Cell"},{"key":"275_CR15","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"JC Marshall","year":"2020","unstructured":"Marshall, J. C. et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20, e192\u2013e197 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"275_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamainternmed.2020.8360","volume":"181","author":"KE Lowe","year":"2021","unstructured":"Lowe, K. E., Zein, J., Hatipoglu, U. & Attaway, A. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the Cleveland Clinic COVID-19 registry. JAMA Intern. Med. 181, 709\u2013711 (2021).","journal-title":"JAMA Intern. Med."},{"key":"275_CR17","doi-asserted-by":"publisher","first-page":"e2029058","DOI":"10.1001\/jamanetworkopen.2020.29058","volume":"3","author":"N Rosenthal","year":"2020","unstructured":"Rosenthal, N., Cao, Z., Gundrum, J., Sianis, J. & Safo, S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw. Open 3, e2029058 (2020).","journal-title":"JAMA Netw. Open"},{"key":"275_CR18","doi-asserted-by":"publisher","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","volume":"13","author":"D Sterlin","year":"2021","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).","journal-title":"Sci. Transl. Med."},{"key":"275_CR19","doi-asserted-by":"publisher","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.05.015 (2020).","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"275_CR20","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"275_CR21","doi-asserted-by":"publisher","unstructured":"Moderbacher, C. R. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.09.038 (2020).","DOI":"10.1016\/j.cell.2020.09.038"},{"key":"275_CR22","doi-asserted-by":"publisher","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","volume":"5","author":"D Weiskopf","year":"2020","unstructured":"Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol.5, eabd2071 (2020).","journal-title":"Sci. Immunol."},{"key":"275_CR23","doi-asserted-by":"publisher","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science https:\/\/doi.org\/10.1126\/science.abd3871 (2020).","DOI":"10.1126\/science.abd3871"},{"key":"275_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.annonc.2020.10.473","volume":"32","author":"A Marra","year":"2021","unstructured":"Marra, A. et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. Ann. Oncol. 32, 113\u2013119 (2021).","journal-title":"Ann. Oncol."},{"key":"275_CR25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","volume":"12","author":"S Dispinseri","year":"2021","unstructured":"Dispinseri, S. et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 12, 2670 (2021).","journal-title":"Nat. Commun."},{"key":"275_CR26","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"275_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"275_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"275_CR29","doi-asserted-by":"publisher","unstructured":"Fendler, A. et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-021-00274-w (2021).","DOI":"10.1038\/s43018-021-00274-w"},{"key":"275_CR30","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598\u20131607 (2020).","journal-title":"Nat. Microbiol."},{"key":"275_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"275_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","volume":"595","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426\u2013431 (2021).","journal-title":"Nature"},{"key":"275_CR33","doi-asserted-by":"publisher","unstructured":"Achiron, A. et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther. Adv. Neurol. Disord. https:\/\/doi.org\/10.1177\/17562864211012835 (2021).","DOI":"10.1177\/17562864211012835"},{"key":"275_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. COVID-19 neutralizing antibodies predict disease severity and survival. Cell 184, 476\u2013488.e11 (2021).","journal-title":"Cell"},{"key":"275_CR35","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S1473-3099(21)00568-5","volume":"21","author":"V Vacharathit","year":"2021","unstructured":"Vacharathit, V. et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect. Dis. 21, 1352\u20131354 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"275_CR36","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 26, 1428\u20131434 (2020).","journal-title":"Nat. Med."},{"key":"275_CR37","doi-asserted-by":"publisher","unstructured":"Murugesan, K. et al. Interferon-\u03b3 release assay for accurate detection of severe acute respiratory syndrome coronavirus 2 T-cell response. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1537 (2020).","DOI":"10.1093\/cid\/ciaa1537"},{"key":"275_CR38","doi-asserted-by":"publisher","first-page":"107827","DOI":"10.1016\/j.celrep.2020.107827","volume":"31","author":"KE Pauken","year":"2020","unstructured":"Pauken, K. E. et al. The PD-1 pathway regulates development and function of memory CD8+ T cells following respiratory viral infection. Cell Rep. 31, 107827 (2020).","journal-title":"Cell Rep."},{"key":"275_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2567.2009.03216.x","volume":"130","author":"JE Konkel","year":"2010","unstructured":"Konkel, J. E. et al. PD-1 signalling in CD4+ T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. Immunology 130, 92\u2013102 (2010).","journal-title":"Immunology"},{"key":"275_CR40","doi-asserted-by":"publisher","first-page":"9318","DOI":"10.1128\/JVI.01049-10","volume":"84","author":"J Zhao","year":"2010","unstructured":"Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318\u20139325 (2010).","journal-title":"J. Virol."},{"key":"275_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Mu\u00f1oz-Fontela","year":"2020","unstructured":"Mu\u00f1oz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"275_CR42","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).","journal-title":"Cell Rep."},{"key":"275_CR43","doi-asserted-by":"publisher","unstructured":"Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100355 (2021).","DOI":"10.1016\/j.xcrm.2021.100355"},{"key":"275_CR44","doi-asserted-by":"publisher","unstructured":"Apostolidis, S.A. et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01507-2 (2021).","DOI":"10.1038\/s41591-021-01507-2"},{"key":"275_CR45","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"275_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer, K. J. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat. Med. 27, 270\u2013278 (2021).","journal-title":"Nat. Med."},{"key":"275_CR47","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1056\/NEJMc2110716","volume":"385","author":"J Normark","year":"2021","unstructured":"Normark, J. et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N. Engl. J. Med. 385, 1049\u20131051 (2021).","journal-title":"N. Engl. J. Med."},{"key":"275_CR48","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med. 27, 1525\u20131529 (2021).","journal-title":"Nat. Med."},{"key":"275_CR49","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41467-021-23173-1","volume":"12","author":"AJ Spencer","year":"2021","unstructured":"Spencer, A.J. et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat. Commun. 12, 2893 (2021).","journal-title":"Nat. Commun."},{"key":"275_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2020.06.027","volume":"136","author":"V Angelis","year":"2020","unstructured":"Angelis, V. et al. Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur. J. Cancer 136, 99\u2013106 (2020).","journal-title":"Eur. J. Cancer"},{"key":"275_CR51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168 (2020).","journal-title":"Cell"},{"key":"275_CR52","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41587-020-0588-y","volume":"38","author":"J Aitken","year":"2020","unstructured":"Aitken, J. et al. Scalable and robust SARS-CoV-2 testing in an academic center. Nat. Biotechnol. 38, 927\u2013931 (2020).","journal-title":"Nat. Biotechnol."},{"key":"275_CR53","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316\u2013319 (2017).","journal-title":"Nat. Biotechnol."},{"key":"275_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-021-00839-5","volume":"13","author":"DJ Baker","year":"2021","unstructured":"Baker, D. J. et al. CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes. Genome Med. 13, 21 (2021).","journal-title":"Genome Med."},{"key":"275_CR55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"275_CR56","doi-asserted-by":"publisher","first-page":"e69317","DOI":"10.7554\/eLife.69317","volume":"10","author":"N Faulkner","year":"2021","unstructured":"Faulkner, N. et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife 10, e69317 (2021).","journal-title":"eLife"},{"key":"275_CR57","doi-asserted-by":"publisher","first-page":"e3001091","DOI":"10.1371\/journal.pbio.3001091","volume":"19","author":"SJ Rihn","year":"2021","unstructured":"Rihn, S. J. et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biol. 19, e3001091 (2021).","journal-title":"PLoS Biol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00275-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00275-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00275-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:53:10Z","timestamp":1670082790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00275-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["275"],"URL":"https:\/\/doi.org\/10.1038\/s43018-021-00275-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-916427\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T. has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen. S.T. has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018\/051892 and PCTGB2018\/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. N.Y. has received conference support from Celegene. A.R. received speaker\u2019s fees from Janssen and AstraZeneca; travel support from Janssen and Astellas, and consultancy fees from AstraZeneca. D.C. received funding from MedImmune, AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene and Roche, and is on the advisory board of OVIBIO. J.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics and Aveo, and served as a consultant to Achilles, Astra Zeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna and Vitaccess. I.C. has served as a consultant to Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck Serono, Five Prime Therapeutics, Astra Zeneca, OncXerna, Pierre Fabre, Boehringer-Ingelheim, Incyte, Astella, GSK, Sotio and, Eisai; has received research funding from Eli-Lilly & Janssen-Cilag; and has received honorarium from Eli-Lilly, Eisai, Servier. A.O. acknowledges receipt of research funding from Pfizer and Roche; speakers fees from Pfizer, Seagen, Lilly and Astra Zeneca; is an advisory board member of Roche, Seagen and Astra Zeneca; and has received conference support from Leo Pharmaceuticals, Astra Zeneca\/Diachi-Sankyo and Lilly. C. Swanton acknowledges grant support from Pfizer, Astra Zeneca, Bristol-Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical; is an Astra Zeneca Advisory Board member and Chief Investigator for the MeRmaiD1 clinical trial; has consulted for Amgen, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol-Myers Squibb, Celgene, Astra Zeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics and the Sarah Cannon Research Institute; has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL and has stock options; and is co-founder of Achilles Therapeutics. C. Swanton holds European patents relating to assay technology to detect tumor recurrence (PCT\/GB2017\/053289); to targeting neoantigens (PCT\/EP2016\/059401), identifying patent response to immune-checkpoint blockade (PCT\/EP2016\/071471), determining HLA LOH (human leukocyte antigen loss of heterozygosity) (PCT\/GB2018\/052004), predicting survival rates of patients with cancer (PCT\/GB2020\/050221), identifying patients who respond to cancer treatment (PCT\/GB2018\/051912), a US patent relating to detecting tumor mutations (PCT\/US2017\/28013) and both a European and US patent related to identifying insertion\/deletion mutation targets (PCT\/GB2018\/051892). L.P. has received research funding from Pierre Fabre and honoraria from Pfizer, Ipsen, Bristol-Myers Squibb and EUSA Pharma. S.B. has received institutional research funding from AstraZeneca, Tesaro, GSK; speakers fees from Amgen, Pfizer, Astra Zeneca, Tesaro, GSK, Clovis, Takeda, Immunogen and Mersana; and has an advisory role for Amgen, AstraZeneca, Epsilogen, Genmab, Immunogen, Mersana, Merck Sharp & Dohme, Merck Serono, Oncxerna, Pfizer and Roche. N.T. has received advisory board honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche\/Genentech, GlaxoSmithKline, Zentalis Pharmaceuticals, Repare Therapeutics and Arvinas; and research funding from AstraZeneca, BioRad, Pfizer, Roche\/Genentech, Merck Sharpe & Dohme, Guardant Health, Invitae, Inivata, Personalis and Natera. M.O.B. is on advisory boards for Amgen, Pierre Fabre, Pharmamar, Puma, MSD and Roche. A.M.S. received and educational grant from Janssen-Cilag. N.S. received travel grants from AstraZeneca, BMS, Eli Lilly, Merck, Roche and MSD Oncology; received honoraria from Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier, GSK and Amgen; and is on the advisory board for Pfizer, AstraZeneca, Servier and MSD. N.S. received funding from AstraZeneca, BMS, Pfizer, NIHR EME, RMCC and RM\/ICR BCR. R.L.J. received research support from Merck Sharp & Dohme and GSK; and received consultation fees from Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Cinigen, Eisai, Epizyme, Daichii, Deciphera, Immundesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks, SynOx, Tracon, Upto Date and Merck Sharp & Dohme<i>.<\/i> A.F., L.A., S.T.C.S., F.B., M.C., L.A.B., K.R., W.G., B.S., C.L.G., B.W., W.X., N.J.-H., G.H.C., M.P., L.M., K.W.N., E.C., K.E., L.D.R., S.S., K.L., M.M., L.H., H.A., R.S., C.G., H.R.F., A.A.-D., P.H., S.C., M.H., M.W., R.G., M.C., L.C., H.P., M.G., E.N., A.-.S., J.I.M., J.N., F.G., R.L.S., C.M., D.C. L.W., N.v.A., J.D., K.C.T., S.J., O.C., K.H., S.B., J.B., A. Robinson, C. Stephenson, T.S., Y.K., Z.T., I.L., S.G., A.O., A. Reid, K.Y., A.J.S.F., S. Gamblin, C. Swanton, E.N., S.K., K.A.W., A.S., R.H., G.K. and R.J.W. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}